Protection against inhalation anthrax by immunization with Salmonella enterica serovar Typhi Ty21a stably producing protective antigen of Bacillus anthracis
B. Kim Lee Sim,
Minglin Li,
Manuel Osorio,
Yun Wu,
Tint T. Wai,
Johnny W. Peterson,
Eric R. James,
Sumana Chakravarty,
Lixin Gao,
Rui Xu,
Natasha KC,
Richard E. Stafford,
William S. Lawrence,
Linsey A. Yeager,
Jennifer E. Peel,
Satheesh K. Sivasubramani,
Ashok K. Chopra,
Svetlana Filippova,
Stephen L. Hoffman
Affiliations
B. Kim Lee Sim
Protein Potential LLC
Minglin Li
Protein Potential LLC
Manuel Osorio
U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER)
Yun Wu
Protein Potential LLC
Tint T. Wai
Protein Potential LLC
Johnny W. Peterson
Department of Microbiology and Immunology, Galveston National Laboratory, Center for Biodefense and Emerging Infectious Diseases, and Sealy Center for Vaccine Development, University of Texas Medical Branch
Eric R. James
Sanaria Inc
Sumana Chakravarty
Sanaria Inc
Lixin Gao
Protein Potential LLC
Rui Xu
Protein Potential LLC
Natasha KC
Protein Potential LLC
Richard E. Stafford
Protein Potential LLC
William S. Lawrence
Department of Microbiology and Immunology, Galveston National Laboratory, Center for Biodefense and Emerging Infectious Diseases, and Sealy Center for Vaccine Development, University of Texas Medical Branch
Linsey A. Yeager
Department of Microbiology and Immunology, Galveston National Laboratory, Center for Biodefense and Emerging Infectious Diseases, and Sealy Center for Vaccine Development, University of Texas Medical Branch
Jennifer E. Peel
Department of Microbiology and Immunology, Galveston National Laboratory, Center for Biodefense and Emerging Infectious Diseases, and Sealy Center for Vaccine Development, University of Texas Medical Branch
Satheesh K. Sivasubramani
Department of Microbiology and Immunology, Galveston National Laboratory, Center for Biodefense and Emerging Infectious Diseases, and Sealy Center for Vaccine Development, University of Texas Medical Branch
Ashok K. Chopra
Department of Microbiology and Immunology, Galveston National Laboratory, Center for Biodefense and Emerging Infectious Diseases, and Sealy Center for Vaccine Development, University of Texas Medical Branch
Svetlana Filippova
U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER)
Counterterrorism: creating a safe, stable, easily stored anthrax vaccine A vaccine candidate for anthrax infection shows promise for improving preparedness for a biological attack. Bacillus anthracis, the bacterium responsible for anthrax is a top-tier bioterrorism agent due to its high lethality and spore stability. The current FDA-approved anthrax vaccine and other vaccine candidates in development lack ease of preparation, have short shelf lives and adverse effects. B. Kim Lee Sim of Protein Potential LLC and her collaborators combined key B. anthracis genetic material into an existing typhoid vaccine. The vaccine vector possesses high stability, a strong safety record, and offers long-term protection after oral administration, which Sim’s group hopes to preserve in their candidate anthrax vaccine. The team showed that their hybrid vaccine conferred excellent protection in rabbits and a short vaccination regimen, and suggest further studies into its suitability for human vaccine studies.
